- Home
- JPI vs DBVT Comparison
JPI vs DBVT Comparison
Compare JPI & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPI
- DBVT
- Stock Information
- Founded
- JPI 2012
- DBVT 2002
- Country
- JPI United States
- DBVT France
- Employees
- JPI N/A
- DBVT N/A
- Industry
- JPI Finance Companies
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JPI Finance
- DBVT Health Care
- Exchange
- JPI Nasdaq
- DBVT Nasdaq
- Market Cap
- JPI 288.1M
- DBVT 260.5M
- IPO Year
- JPI N/A
- DBVT N/A
- Fundamental
- Price
- JPI $20.69
- DBVT $9.87
- Analyst Decision
- JPI
- DBVT Buy
- Analyst Count
- JPI 0
- DBVT 4
- Target Price
- JPI N/A
- DBVT $14.81
- AVG Volume (30 Days)
- JPI 54.7K
- DBVT 33.2K
- Earning Date
- JPI 01-01-0001
- DBVT 11-05-2025
- Dividend Yield
- JPI 6.15%
- DBVT N/A
- EPS Growth
- JPI N/A
- DBVT N/A
- EPS
- JPI N/A
- DBVT N/A
- Revenue
- JPI N/A
- DBVT $3,800,000.00
- Revenue This Year
- JPI N/A
- DBVT $1,743.46
- Revenue Next Year
- JPI N/A
- DBVT $1,045.66
- P/E Ratio
- JPI N/A
- DBVT N/A
- Revenue Growth
- JPI N/A
- DBVT N/A
- 52 Week Low
- JPI $16.02
- DBVT $2.21
- 52 Week High
- JPI $19.12
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- JPI 63.07
- DBVT 55.10
- Support Level
- JPI $20.51
- DBVT $9.58
- Resistance Level
- JPI $20.70
- DBVT $10.50
- Average True Range (ATR)
- JPI 0.15
- DBVT 0.51
- MACD
- JPI 0.04
- DBVT 0.07
- Stochastic Oscillator
- JPI 91.53
- DBVT 64.92
About JPI Nuveen Preferred and Income Term Fund of Beneficial Interest
Nuveen Preferred and Income Term Fund is a closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The company's products include mutual funds, closed-end funds, Exchange-traded funds, Multi-asset model portfolios, and others.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.